PMID- 37312616
OWN - NLM
STAT- MEDLINE
DCOM- 20231023
LR  - 20231026
IS  - 1478-3231 (Electronic)
IS  - 1478-3223 (Linking)
VI  - 43
IP  - 11
DP  - 2023 Nov
TI  - Associations between higher plasma ferritin and hepcidin levels with liver 
      stiffness in patients with type 2 diabetes: An exploratory study.
PG  - 2434-2444
LID - 10.1111/liv.15649 [doi]
AB  - BACKGROUND: Currently, there is no information about the association between 
      circulating levels of ferritin and hepcidin and liver fibrosis in patients with 
      type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD). 
      METHODS: We enrolled 153 patients with T2DM with no known liver diseases, who 
      consecutively attended our diabetes outpatient service and who underwent liver 
      ultrasonography and liver stiffness measurement (LSM) by vibration-controlled 
      transient elastography (Fibroscan((R)) for the non-invasive assessment of liver 
      fibrosis). Plasma ferritin and hepcidin concentrations were measured with an 
      electrochemiluminescence immunoassay and mass spectrometry-based assay, 
      respectively. RESULTS: After stratification of patients by LSM tertiles [1st 
      tertile median LSM: 3.6 (interquartile range: 3.3-4.0) kPa, 2nd tertile: 5.3 
      (4.9-5.9) kPa and 3rd tertile: 7.9 (6.7-9.4) kPa], we found that plasma ferritin 
      and hepcidin concentrations increased across LSM tertiles [median ferritin: 68.7 
      (interquartile range: 25.1-147) vs. 85.8 (48.3-139) vs. 111 (59.3-203) mug/L, 
      p = 0.021; median hepcidin: 2.5 (1.1-5.2) vs. 4.4 (2.5-7.3) vs. 4.1 (1.9-6.8) 
      nmol/L, p = 0.032]. After adjustment for age, sex, diabetes duration, waist 
      circumference, haemoglobin A1c, HOMA-insulin resistance score, triglycerides, 
      haemoglobin, presence of hepatic steatosis on ultrasonography and patatin-like 
      phospholipase domain-containing-3 (PNPLA3) rs738409 genetic variant, higher 
      plasma ferritin levels were associated with greater LSM values (adjusted-odds 
      ratio 2.10, 95% confidence interval 1.23-3.57, p = 0.005). Higher plasma hepcidin 
      levels were also associated with greater LSM values (adjusted-odds ratio 1.90, 
      95% confidence interval 1.15-3.13, p = 0.013). CONCLUSIONS: Higher levels of 
      plasma ferritin and hepcidin were associated with greater NAFLD-related liver 
      fibrosis (assessed by LSM) in patients with T2DM, even after adjustment for 
      established cardiometabolic risk factors, diabetes-related variables and other 
      potential confounders.
CI  - (c) 2023 The Authors. Liver International published by John Wiley & Sons Ltd.
FAU - Mantovani, Alessandro
AU  - Mantovani A
AUID- ORCID: 0000-0002-7271-6329
AD  - Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, 
      University of Verona and Azienda Ospedaliera Universitaria Integrata of Verona, 
      Verona, Italy.
FAU - Csermely, Alessandro
AU  - Csermely A
AUID- ORCID: 0000-0002-3420-4998
AD  - Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, 
      University of Verona and Azienda Ospedaliera Universitaria Integrata of Verona, 
      Verona, Italy.
FAU - Castagna, Annalisa
AU  - Castagna A
AD  - Department of Medicine, Section of Internal Medicine, EuroBloodNet Center, 
      University of Verona and Azienda Ospedaliera Universitaria Integrata Verona, 
      Verona, Italy.
FAU - Antinori, Elisa
AU  - Antinori E
AD  - Department of Medicine, Section of Internal Medicine, EuroBloodNet Center, 
      University of Verona and Azienda Ospedaliera Universitaria Integrata Verona, 
      Verona, Italy.
FAU - Danese, Elisa
AU  - Danese E
AD  - Section of Clinical Biochemistry, Department of Engineering for Innovation 
      Medicine, University of Verona, Verona, Italy.
FAU - Zusi, Chiara
AU  - Zusi C
AD  - Pediatric Diabetes and Metabolic Disorders Unit, Department of Surgical Sciences, 
      Dentistry, Pediatrics and Gynaecology, University Hospital of Verona, Verona, 
      Italy.
FAU - Sani, Elena
AU  - Sani E
AD  - Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, 
      University of Verona and Azienda Ospedaliera Universitaria Integrata of Verona, 
      Verona, Italy.
FAU - Ravaioli, Federico
AU  - Ravaioli F
AUID- ORCID: 0000-0002-1142-8585
AD  - Gastroenterology Unit, Department of Medical Specialities, University Hospital of 
      Modena, University of Modena & Reggio Emilia, Modena, Italy.
FAU - Colecchia, Antonio
AU  - Colecchia A
AD  - Gastroenterology Unit, Department of Medical Specialities, University Hospital of 
      Modena, University of Modena & Reggio Emilia, Modena, Italy.
FAU - Maffeis, Claudio
AU  - Maffeis C
AUID- ORCID: 0000-0002-3563-4404
AD  - Pediatric Diabetes and Metabolic Disorders Unit, Department of Surgical Sciences, 
      Dentistry, Pediatrics and Gynaecology, University Hospital of Verona, Verona, 
      Italy.
FAU - Valenti, Luca
AU  - Valenti L
AUID- ORCID: 0000-0001-8909-0345
AD  - Precision Medicine-Biological Resource Center, Transfusion Medicine, Fondazione 
      IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano, Milan, Italy.
AD  - Department of Pathophysiology and Transplantation, University of Milan, Milan, 
      Italy.
FAU - Girelli, Domenico
AU  - Girelli D
AD  - Department of Medicine, Section of Internal Medicine, EuroBloodNet Center, 
      University of Verona and Azienda Ospedaliera Universitaria Integrata Verona, 
      Verona, Italy.
FAU - Targher, Giovanni
AU  - Targher G
AUID- ORCID: 0000-0002-4325-3900
AD  - Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, 
      University of Verona and Azienda Ospedaliera Universitaria Integrata of Verona, 
      Verona, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230614
PL  - United States
TA  - Liver Int
JT  - Liver international : official journal of the International Association for the 
      Study of the Liver
JID - 101160857
RN  - 0 (Hepcidins)
RN  - 0 (Glycated Hemoglobin)
SB  - IM
CIN - Liver Int. 2023 Nov;43(11):2571-2575. PMID: 37752888
MH  - Humans
MH  - *Diabetes Mellitus, Type 2
MH  - *Non-alcoholic Fatty Liver Disease/genetics
MH  - Hepcidins
MH  - Liver/diagnostic imaging/pathology
MH  - Liver Cirrhosis/complications
MH  - *Elasticity Imaging Techniques
MH  - Glycated Hemoglobin
OTO - NOTNLM
OT  - fatty liver
OT  - ferritin
OT  - hepcidin
OT  - liver stiffness measurement
OT  - non-alcoholic fatty liver disease
OT  - type 2 diabetes
EDAT- 2023/06/14 06:42
MHDA- 2023/10/23 00:44
CRDT- 2023/06/14 03:42
PHST- 2023/05/11 00:00 [revised]
PHST- 2023/04/01 00:00 [received]
PHST- 2023/06/05 00:00 [accepted]
PHST- 2023/10/23 00:44 [medline]
PHST- 2023/06/14 06:42 [pubmed]
PHST- 2023/06/14 03:42 [entrez]
AID - 10.1111/liv.15649 [doi]
PST - ppublish
SO  - Liver Int. 2023 Nov;43(11):2434-2444. doi: 10.1111/liv.15649. Epub 2023 Jun 14.